Skye Bioscience, Inc. annual report, FY2015

Vollständiges Dokument

Filing summary

Issuer and period: The supplied filing is Nemus Bioscience, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 18, 2016. This does not match the request metadata naming Skye Bioscience, Inc. or describing the period as 2015 Q4; verify the issuer and filing before relying on this summary.

Business context and reporting period

Nemus was an early-stage biopharmaceutical company developing cannabinoid-based therapeutics in partnership with the University of Mississippi (UM). Its candidates were in research or preclinical development; it had no approved products, product revenue, or established commercialization infrastructure. The 2014 comparison period reflects Nemus as the accounting acquirer in a reverse merger completed in October 2014.

Financial results and liquidity

  • Revenue: None in 2015 or 2014. Gross margin and operating margin are therefore not meaningful.
  • Operating expenses: $4.32 million in 2015, up from $2.73 million in 2014. Research and development was $576,093, versus $227,500; general and administrative expense was $3.74 million, versus $2.50 million.
  • Loss: Net loss was $4.84 million, compared with $2.73 million in 2014. Basic and diluted loss per share was $0.29, versus $0.27.
  • Unusual non-operating items: Net other expense was $522,335, principally a $986,000 charge for the Series A preferred-stock conversion feature, partly offset by $481,610 of income from a decrease in the fair value of Series B warrants; the Series B conversion feature added $17,945 of expense. These fair-value items affected reported loss.
  • Cash flow: Net cash used in operating activities was $3.73 million, compared with $1.76 million in 2014. Investing cash use was $1,982. Financing provided $6.74 million, including net proceeds from common and preferred stock issuance.
  • Cash and assets: Cash and cash equivalents were $3.22 million at year-end, versus $207,330 a year earlier; an additional $37,500 was restricted as credit-card collateral. Total current assets were $3.45 million and total assets were $3.51 million.
  • Liabilities and capitalization: Total liabilities were $3.04 million, including a $2.45 million Series B warrant liability; current liabilities were $581,860. The balance sheet also reported $1.36 million of redeemable Series B preferred stock outside liabilities, with a $4.5 million liquidation preference. No conventional interest-bearing debt is identified in the supplied financial statements.
  • Going concern: The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern because of recurring losses and dependence on additional financing. Management said funds would not cover obligations within one year after issuance without additional funding. Elsewhere, the risk disclosure says existing cash would not fund requirements for at least the next two months; the differing runway statements merit verification.

Material changes versus 2014

  • Operating expenses rose 58%, while net loss increased by approximately $2.11 million. R&D expense increased with additional licenses, renewals, options, and UM research; G&A rose mainly with salaries, consulting, professional fees, stock compensation, and public-company costs.
  • Cash increased by about $3.01 million, primarily following the $5.0 million gross Series B financing in August 2015. Operating cash use also increased.
  • The Series A financing converted following the Series B financing, including additional common shares under Series A down-round protection. A Series B holder converted 500 preferred shares into 625,000 common shares by year-end.
  • Common shares outstanding increased from 16.0 million at December 31, 2014 to 19.9 million at December 31, 2015. The Series B financing also included warrants for 6.25 million common shares, adding potential dilution.

Outlook, risks, contingencies, and unusual items

  • Development plans: NB1111 for glaucoma was preclinical. Rabbit studies reported IOP reductions, including approximately 20% and 35% with two nanoparticle doses, but management was pursuing sustained-release delivery and said an IND submission depended on obtaining a delivery device and completing enabling work. NB1222 for chemotherapy-induced nausea and vomiting was being considered for a 505(b)(2) pathway; management planned to request an FDA pre-NDA meeting in the first half of 2016. CBD candidates for CIPN and MRSA remained at research stage.
  • Funding outlook: Management expected continued losses and significant R&D, public-company, laboratory, and staffing costs. It was seeking additional financing; no assurance was given that funds would be available on acceptable terms. Equity financing could materially dilute shareholders, while debt or strategic arrangements could restrict operations or require surrender of rights.
  • Regulatory and partner dependence: Cannabis is federally Schedule I. Nemus had not obtained DEA controlled-substance registrations, and development depended heavily on UM and navigating federal, state, and international rules. The filing identifies regulatory approval, trial outcomes, manufacturing, and continued access to UM technology as major uncertainties.
  • Financing terms and dilution: Series B preferred stock carried a $4.5 million year-end liquidation preference, down-round protection, and redemption rights upon specified triggering events. The company also disclosed substantial authorized share capacity and outstanding warrants and options.
  • Litigation: A former CEO sued the company and its executive chairman in December 2015, alleging claims including breach of contract and seeking unspecified damages and fees. The company disputed the allegations and said it intended to pursue claims against the former CEO. The filing does not provide a quantified exposure.
  • Subsequent event: In February 2016, the company entered an agreement with Albany Molecular Research Inc. for THC prodrug process and analytical-method development, with stated initial estimated fees of approximately $297,000–$326,000, plus further sample-production and stability-study costs.
  • Other context: The common stock traded thinly on the OTCQB, and the filing warned that quotations may not reflect executable prices. No cash dividends were anticipated.

Important facts for investors to verify

  • Confirm that this Nemus Bioscience 2015 Form 10-K—not a Skye Bioscience filing—is the intended document and reporting period.
  • Reconcile the filing’s differing statements about available cash runway and review subsequent financing, cash use, and going-concern disclosures.
  • Check the current status of DEA registrations, the UM partnership and licenses, NB1111 delivery-device plans, and regulatory timelines for all candidates.
  • Review the Series B preferred-stock redemption triggers, warrant and conversion terms, and fully diluted share count for potential dilution and liquidity exposure.
  • Assess the former CEO litigation’s subsequent developments and any related financial-statement or contingency updates.